Posaconazole

Active ingredient: Posaconazole

In short: Posaconazole delayed-release tablets are indicated for the prophylaxis of invasive Aspergillusand Candidainfections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-

Forms & strengthsPosaconazole delayed-release tablets are available as yellow, modified, oval, convex tablets debossed with a logo "M" inside a square on one side and "100" on the opposite side containing 100 mg of posaconazole.
LabelGolden State Medical Supply, Inc.
Label updatedOct 21, 2026

What is Posaconazole used for?

Posaconazole delayed-release tablets are indicated for the prophylaxis of invasive

Aspergillusand

Candidainfections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows:

Posaconazole delayed-release tablets:adults and pediatric patients 13 years of age and older who weigh greater than 40 kg

Additional Pediatric Use information is approved for Merck Sharp & Dohme Corp.’s NOXAFIL

(posaconazole)

delayed-release tablets. However, due to Merck Sharp & Dohme Corp.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

Posaconazole dosage

Non-substitutable

Posaconazole delayed-release tablets are not substitutable with Noxafil

®Oral Suspension or Noxafil

®PowderMix for Delayed-Release Oral Suspension due to the differences in the dosing of each formulation. Therefore, follow the specific dosage recommendations for each of the formulations

.

Posaconazole delayed-release tablets

Swallow tablets whole. Do not divide, crush, or chew.

Administer with or without food

.

For patients who cannot eat a full meal, posaconazole delayed-release tablets should be used instead of Noxafil

®Oral Suspension for the prophylaxis indication. Posaconazole delayed-release tablets generally provide higher plasma drug exposures than Noxafil

®Oral Suspension under both fed and fasted conditions.

The recommended dosage of posaconazole delayed-release tablets in adult patients for prophylaxis of invasive

Aspergillus and

Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised is shown in Table 1

.

Dosage | Duration of Therapy

Prophylaxis of Invasive

Aspergillusand

CandidaInfections

Posaconazole Delayed-Release Tablets:

Loading dose: 300 mg (three 100 mg delayed-release tablets) twice a day on the first day.

Maintenance dose: 300 mg (three 100 mg delayed-release tablets) once a day, starting on the second day. | Loading dose:

1 day

Maintenance dose:Duration of therapy is based on recovery from neutropenia or immunosuppression

Posaconazole delayed-release tablets

The recommended dosage of posaconazole delayed-release tablets in pediatric patients 13 years of age and older who weigh greater than 40 kg for the prophylaxis of invasive

Aspergillusand

Candidainfections is shown in Table

2

.

Posaconazole delayed-release tablets are not recommended for use in pediatric patients who weigh 40 kg or less because the recommended dosage cannot be achieved with this dosage form.

Recommended Pediatric Dosage by Formulation | Duration of Therapy

Posaconazole Delayed-Release Tablets (patients weighing greater than 40 kg):

Loading dose:

300 mg (three 100 mg delayed-release tablets) twice a day on the first day.

Maintenance dose:

300 mg (three 100 mg delayed-release tablets) once a day, starting on the second day. | Prophylaxis of invasive

Aspergillusand

Candidainfections:

Duration of therapy is based on recovery from neutropenia or immunosuppression.

Additional Pediatric Use information is approved for Merck Sharp & Dohme Corp.’s NOXAFIL

(posaconazole)

delayed-release tablets. However, due to Merck Sharp & Dohme Corp.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information.

Swallow tablets whole. Do not divide, crush, or chew.

Administer posaconazole delayed-release tablets with or without food

. …

How to take Posaconazole — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (

Patient Information).

Important Administration Instructions

Posaconazole Delayed-Release Tablets

Advise patients that posaconazole delayed-release tablets must be swallowed whole and not divided, crushed, or chewed.

Instruct patients that if they miss a dose, they should take it as soon as they remember. If they do not remember until it is within 12 hours of the next dose, they should be instructed to skip the missed dose and go back to the regular schedule. Patients should not double their next dose or take more than the prescribed dose.

Drug Interactions

Advise patients to inform their physician immediately if they:

develop severe diarrhea or vomiting.

are currently taking drugs that are known to prolong the QTc interval and are metabolized through CYP3A4.

are currently taking a cyclosporine or tacrolimus, or they notice swelling in an arm or leg or shortness of breath.

are taking other drugs or before they begin taking other drugs as certain drugs can decrease or increase the plasma concentrations of posaconazole. …

Warnings & precautions

Do not take this medicine if: Posaconazole delayed-release tablets are contraindicated in persons with known hypersensitivity to posaconazole or other azole antifungal agents.

Posaconazole delayed-release tablets are contraindicated with sirolimus. Concomitant administration of posaconazole delayed-release tablets with sirolimus increases the sirolimus blood concentrations by approximately 9-fold and can result in sirolimus toxicity

.

Posaconazole delayed-release tablets are contraindicated with CYP3A4 substrates that prolong the QT interval. Concomitant administration of posaconazole delayed-release tablets with the CYP3A4 substrates, pimozide and quinidine may result in increased plasma concentrations of these drugs, leading to QTc prolongation and cases of torsades de pointes

.

Coadministration with the HMG-CoA reductase inhibitors that are primarily metabolized through CYP3A4 (e.g., atorvastatin, lovastatin, and simvastatin) is contraindicated since increased plasma concentration of these drugs can lead to rhabdomyolysis

.

Posaconazole may increase the plasma concentrations of ergot alkaloids (ergotamine and dihydroergotamine) which may lead to ergotism

.

Coadministration of posaconazole delayed-release tablets with venetoclax at initiation and during the ramp-up phase is contraindicated in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) due to the potential for increased risk of tumor lysis syndrome

.

Concomitant administration of posaconazole delayed-release tablets with cyclosporine or tacrolimus increases the whole blood trough concentrations of these calcineurin-inhibitors

. Nephrotoxicity and leukoencephalopathy (including deaths) have been reported in clinical efficacy studies in patients with elevated cyclosporine or tacrolimus concentrations. …

Posaconazole side effects

The following serious and otherwise important adverse reactions are discussed in detail in another section of the labeling:

Arrhythmias and QT Prolongation

Electrolyte Disturbances

Pseudoaldosteronism

Hepatic Toxicity

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of posaconazole delayed-release tablets cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical Trial Experience with P

osaconazole Delayed-Release Tablets for Prophylaxis of Invasive

Aspergillusand

CandidaInfections

The safety of posaconazole delayed-release tablets has been assessed in 230 patients in clinical trials. Patients were enrolled in a non-comparative pharmacokinetic and safety trial of posaconazole delayed-release tablets when given as antifungal prophylaxis (Posaconazole Delayed-Release Tablet Study). Patients were immunocompromised with underlying conditions including hematological malignancy, neutropenia postchemotherapy, GVHD, and post HSCT. This patient population was 62% male, had a mean age of 51 years (range 19-78 years, 17% of patients were ≥65 years of age), and were 93% White and 16% Hispanic. Posaconazole delayed-release tablets were given for a median duration of 28 days. …

Drug interactions

Table 15 and Table 17 include drugs with clinically important drug interactions when administered concomitantly with posaconazole delayed-release tablets and instructions for preventing or managing them.

These recommendations are based on either drug interaction studies or predicted interactions due to the expected magnitude of interaction and potential for serious adverse reactions or loss of efficacy

.

The following information was derived from data with Noxafil

®oral suspension or another posaconazole tablet formulation unless otherwise noted. All clinically important drug interactions with Noxafil

®oral suspension, except for those that affect the absorption of posaconazole (via gastric pH and motility), are considered relevant to clinically important drug interactions with posaconazole delayed-release tablets

[

Clinical Pharmacology (12.3)]

.

Consult the labeling of concomitantly used drugs to obtain further information about interactions with posaconazole.

Posaconazole is primarily metabolized via UDP-glucuronosyltransferase and is a substrate of p-­-glycoprotein (P-gp) efflux. Therefore, inhibitors or inducers of these clearance pathways may affect posaconazole plasma concentrations. …

About this medicine

Posaconazole delayed-release tablets contain posaconazole, an azole antifungal agent.

Posaconazole is designated chemically as 4-[4-[4-[4-[[ (3

R,5

R)-5- (2,4-difluorophenyl)tetrahydro-5- (1

H-1,2,4-triazol-1-ylmethyl)-3-furanyl]methoxy]phenyl]-1-piperazinyl]phenyl]-2-[(1

S,2

S)-1-ethyl-2-hydroxypropyl]-2,4-dihydro-3

H-1,2,4-triazol-3-one with an empirical formula of C

37H

42F

2N

8O

4and a molecular weight of 700.8. The chemical structure is:

Posaconazole is a white powder with a low aqueous solubility.

Posaconazole delayed-release tablets are yellow, modified, oval, convex tablets containing 100 mg of posaconazole. Each delayed-release tablet contains the inactive ingredients: Hypromellose Acetate Succinate, Microcrystalline Cellulose, Hydroxypropyl Cellulose, Croscarmellose Sodium, Silicon Dioxide, and Magnesium Stearate. The color coating contains (Polyvinyl Alcohol, Titanium Dioxide, Polyethylene Glycol, Talc, Ferric Oxide Yellow, and Ferrosoferric Oxide).

How it works: Posaconazole is an azole antifungal agent . …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e883b495-d7e7-6d58-e053-2a95a90a1cd3. Read the full official label on DailyMed.